Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence

World Journal of Gastroenterology

Volumn 19, Issue 47, 2013, Pages 8895-8901

  Tan, Zhong Ming ^a,b   Sun, Bei Cheng ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

Antiviral therapy; Carcinogenesis; Clinical trial; Hepatocelluar carcinoma; Interferon; Nucleos(t)ide analogues; Recurrence; Retrospective study

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AMINOTRANSFERASE; ENTECAVIR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LAMIVUDINE; NUCLEOTIDE; PLACEBO; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; VIRUS PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; CANCER CONTROL; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC INFLAMMATION; DENDRITIC CELL; DISEASE FREE SURVIVAL; DNA METHYLATION; GENOTYPE; HEPATITIS B; HISTONE MODIFICATION; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER RESECTION; LIVER TRANSPLANTATION; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIA; VIRUS REPLICATION;

ANTIVIRAL THERAPY; CARCINOGENESIS; CLINICAL TRIAL; HEPATOCELLUAR CARCINOMA; INTERFERON; NUCLEOS(T)IDE ANALOGUES; RECURRENCE; RETROSPECTIVE STUDY;

ANIMALS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, VIRAL; HEPATECTOMY; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 84890897962     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i47.8895     Document Type: Article

References (56)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576 [PMID: 17570226 DOI: 10.1053/ j.gastro.2007.04.061]
2. Sherman M. Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment. Cleve Clin J Med 2009; 76 Suppl 3: S6-S9 [PMID: 19465708 DOI: 10.3949/ccjm.76.s3.02]
3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.e1 [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061]
4. Lim KC, Chow PK, Allen JC, Siddiqui FJ, Chan ES, Tan SB. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br J Surg 2012; 99: 1622-1629 [PMID: 23023956 DOI: 10.1002/bjs.8915]
5. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229 [PMID: 15738952 DOI: 10.1038/nri1573]
6. Sun BS, Pan J, Clayton MM, Liu J, Yan X, Matskevich AA, Strayer DS, Gerber M, Feitelson MA. Hepatitis C virus replication in stably transfected HepG2 cells promotes hepatocellular growth and tumorigenesis. J Cell Physiol 2004; 201: 447-458 [PMID: 15389552 DOI: 10.1002/jcp.20083]
7. Broering R, Lu M, Schlaak JF. Role of Toll-like receptors in liver health and disease. Clin Sci (Lond) 2011; 121: 415-426 [PMID: 21797822 DOI: 10.1042/ CS20110065]
8. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012; 61 Suppl 1: 16-17 [PMID: 22504921 DOI: 10.1136/gutjnl-2012-302056]
9. Sun B, Karin M. Inflammation and liver tumorigenesis. Front Med 2013; 7: 242-254 [PMID: 23681888 DOI: 10.1007/ s11684-013-0256-4]
10. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-466 [PMID: 15329734 DOI: 10.1038/nature02924]
11. Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J Virol 2004; 78: 12725-12734 [PMID: 15542625 DOI: 10.1128/ JVI.78.23.12725-12734.2004]
12. Chirillo P, Falco M, Puri PL, Artini M, Balsano C, Levrero M, Natoli G. Hepatitis B virus pX activates NF-kappa B-de-pendent transcription through a Raf-independent pathway. J Virol 1996; 70: 641-646 [PMID: 8523586]
13. Weil R, Sirma H, Giannini C, Kremsdorf D, Bessia C, Darge-mont C, Bréchot C, Israël A. Direct association and nuclear import of the hepatitis B virus X protein with the NF-kappaB inhibitor IkappaBalpha. Mol Cell Biol 1999; 19: 6345-6354 [PMID: 10454581]
14. Benn J, Su F, Doria M, Schneider RJ. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases. J Virol 1996; 70: 4978-4985 [PMID: 8764004]
15. Yen CJ, Lin YJ, Yen CS, Tsai HW, Tsai TF, Chang KY, Huang WC, Lin PW, Chiang CW, Chang TT. Hepatitis B virus X protein upregulates mTOR signaling through IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS One 2012; 7: e41931 [PMID: 22848663 DOI: 10.1371/journal.pone.0041931]
16. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammations and cancer. Trends Mol Med 2008; 14: 109-119 [PMID: 18261959 DOI: 10.1016/j.molmed.2007.12.007]
17. Jiang R, Tan Z, Deng L, Chen Y, Xia Y, Gao Y, Wang X, Sun B. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011; 54: 900-909 [PMID: 21674558 DOI: 10.1002/hep.24486]
18. Zhang Z, Zhang S, Zou Z, Shi J, Zhao J, Fan R, Qin E, Li B, Li Z, Xu X, Fu J, Zhang J, Gao B, Tian Z, Wang FS. Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology 2011; 53: 73-85 [PMID: 21254163 DOI: 10.1002/hep.23977]
19. van der Molen RG, Sprengers D, Binda RS, de Jong EC, Niesters HG, Kusters JG, Kwekkeboom J, Janssen HL. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 2004; 40: 738-746 [PMID: 15349914 DOI: 10.1002/hep.20366]
20. Li J, Qiu SJ, She WM, Wang FP, Gao H, Li L, Tu CT, Wang JY, Shen XZ, Jiang W. Significance of the balance between regulatory T (Treg) and T helper 17 (Th17) cells during hepatitis B virus related liver fibrosis. PLoS One 2012; 7: e39307 [PMID: 22745730 DOI: 10.1371/journal.pone.0039307]
21. Tan YJ. Hepatitis B virus infection and the risk of hepatocel-lular carcinoma. World J Gastroenterol 2011; 17: 4853-4857 [PMID: 22171125 DOI: 10.3748/wjg.v17.i44.4853]
22. Aoki H, Kajino K, Arakawa Y, Hino O. Molecular cloning of a rat chromosome putative recombinogenic sequence homologous to the hepatitis B virus encapsidation signal. Proc Natl Acad Sci USA 1996; 93: 7300-7304 [PMID: 8692987]
23. Zhang X, You X, Li N, Zhang W, Gagos S, Wang Q, Banos A, Cai N, Zhang H, Zhang H, Zhang X, Shan C, Qiu L, Zhang S, Lv N, Chen M, Du Y, Xia J, Ye L, Zhang X. Involvement of hepatitis B virus X gene (HBx) integration in hepatocar-cinogenesis via a recombination of HBx/Alu core sequence/ subtelomeric DNA. FEBS Lett 2012; 586: 3215-3221 [PMID: 22771476 DOI: 10.1016/j.febslet.2012.06.039]
24. Wang J, Chenivesse X, Henglein B, Bréchot C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 1990; 343: 555-557 [PMID: 1967822 DOI: 10.1038/343555a0]
25. Fallot G, Neuveut C, Buendia MA. Diverse roles of hepatitis B virus in liver cancer. Curr Opin Virol 2012; 2: 467-473 [PMID: 22722078 DOI: 10.1016/j.coviro.2012.05.008]
26. Terradillos O, Billet O, Renard CA, Levy R, Molina T, Briand P, Buendia MA. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 1997; 14: 395-404 [PMID: 9053836 DOI: 10.1038/ sj.onc.1200850]
27. Kojima H, Kaita KD, Xu Z, Ou JH, Gong Y, Zhang M, Mi-nuk GY. The absence of up-regulation of telomerase activity during regeneration after partial hepatectomy in hepatitis B virus X gene transgenic mice. J Hepatol 2003; 39: 262-268 [PMID: 12873824]
28. Saini N, Srinivasan R, Chawla Y, Sharma S, Chakraborti A, Rajwanshi A. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepato-cellular carcinoma is independent of hepatitis virus status. Liver Int 2009; 29: 1162-1170 [PMID: 19627485 DOI: 10.1111/ j.1478-3231.2009.02082.x]
29. Ng SA, Lee C. Hepatitis B virus X gene and hepatocarcino-genesis. J Gastroenterol 2011; 46: 974-990 [PMID: 21647825 DOI: 10.1007/s00535-011-0415-9]
30. Forgues M, Diflippantonio MJ, Linke SP, Ried T, Nagashi-ma K, Feden J, Valerie K, Fukasawa K, Wang XW. Involvement of Crm1 in hepatitis B virus X protein-induced aberrant centriole replication and abnormal mitotic spindles. Mol Cell Biol 2003; 23: 5282-5292 [PMID: 12861014]
31. Jiang R, Deng L, Zhao L, Li X, Zhang F, Xia Y, Gao Y, Wang X, Sun B. Mir-22 promotes HBV-related hepatocellular carcino-ma development in males. Clin Cancer Res 2011; 17: 5593-5603 [PMID: 21750200 DOI: 10.1158/1078-0432.CCR-10-1734]
32. Xu X, Fan Z, Kang L, Han J, Jiang C, Zheng X, Zhu Z, Jiao H, Lin J, Jiang K, Ding L, Zhang H, Cheng L, Fu H, Song Y, Jiang Y, Liu J, Wang R, Du N, Ye Q. Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest 2013; 123: 630-645 [PMID: 23321675 DOI: 10.1172/ JCI64265]
33. Kapoor NR, Ahuja R, Shukla SK, Kumar V. The HBx protein of hepatitis B virus confers resistance against nucleolar stress and anti-cancer drug-induced p53 expression. FEBS Lett 2013; 587: 1287-1292 [PMID: 23507139 DOI: 10.1016/ j.febslet.2013.03.004]
34. Alberti A, Caporaso N. HBV therapy: guidelines and open issues. Dig Liver Dis 2011; 43 Suppl 1: S57-S63 [PMID: 21195373 DOI: 10.1016/S1590-8658(10)60693-7]
35. Low TL, Goldstein AL. Thymosins: structure, function and therapeutic applications. Thymus 1984; 6: 27-42 [PMID: 6087503]
36. Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 1998; 27: 1383-1387 [PMID: 9581695 DOI: 10.1002/hep.510270527]
37. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-pos-itive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695 [PMID: 15987917 DOI: 10.1056/NEJMoa043470]
38. Yuen MF, Lai CL. Treatment of chronic hepatitis B: Evolution over two decades. J Gastroenterol Hepatol 2011; 26 Suppl 1: 138-143 [PMID: 21199525 DOI: 10.1111/ j.1440-1746.2010.06545.x]
39. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006; 101: 1797-1803 [PMID: 16817842 DOI: 10.1111/j.1572-0241.2006.00647.x]
40. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term benefcial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-975 [PMID: 10051505 DOI: 10.1002/hep.510290312]
41. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531 [PMID: 15470215 DOI: 10.1056/NEJMoa033364]
42. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, Okita K, Hayashi N, Okanoue T, Iino S, Tani-kawa K. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32: 173-184 [PMID: 16024289 DOI: 10.1016/j.hepres.2005.02.006]
43. Di Marco V, Marzano A, Lampertico P, Andreone P, Santan-tonio T, Almasio PL, Rizzetto M, Craxì A. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virolo-gical response to lamivudine. Hepatology 2004; 40: 883-891 [PMID: 15382125 DOI: 10.1002/hep.20381]
44. Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol 2010; 53: 118-125 [PMID: 20471129 DOI: 10.1016/j.jhep.2010.02.026]
45. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-356 [PMID: 20483498 DOI: 10.1016/j.jhep.2010.02.035]
46. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocel-lular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-1077 [PMID: 18657133 DOI: 10.1111/j.1365-2036.2008.03816.x]
47. Dhir M, Lyden ER, Smith LM, Are C. Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis. HPB (Oxford) 2012; 14: 635-645 [PMID: 22882201 DOI: 10.1111/ j.1477-2574.2012.00500.x]
48. Huang G, Lai EC, Lau WY, Zhou WP, Shen F, Pan ZY, Fu SY, Wu MC. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma infuences postoperative survival in patients with preoperative low HBV-DNA levels. Ann Surg 2013; 257: 490-505 [PMID: 22868358 DOI: 10.1097/ SLA.0b013e318262b218]
49. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, Fan ST, Wong J. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245: 831-842 [PMID: 17522506 DOI: 10.1097/01.sla.0000245829.00977.45]
50. Lee D, Chung YH, Kim JA, Park WH, Jin YJ, Shim JH, Ryu SH, Jang MK, Yu E, Lee YJ. Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma. Cancer 2013; 119: 2239-2246 [PMID: 23564564 DOI: 10.1002/cncr.28082]
51. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J, Zhou XD, Zhou J, Qiu SJ, Shen YF. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006; 132: 458-465 [PMID: 16557381 DOI: 10.1007/s00432-006-0091-y]
52. Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, Wu CC, Mok KT, Chen CL, Lee WC, Chau GY, Chen YS, Lui WY, Hsiao CF, Whang-Peng J, Chen PJ. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 2012; 255: 8-17 [PMID: 22104564 DOI: 10.1097/SLA.0b013e3182363ff9]
53. Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, Kunder G, Chen PW, Farmer DG, Yersiz H, Baquer-izo A, Geevarghese S, Han SH, Goldstein L, Holt CD, Gorn-bein JA, Busuttil RW. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002; 235: 611-619; discussion 619-620 [PMID: 11981206]
54. Chan AC, Chok KS, Yuen WK, Chan SC, Poon RT, Lo CM, Fan ST. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg 2011; 146: 675-681.[PMID: 21690443 DOI: 10.1001/archsurg.2011.125]
55. Kubo S, Tanaka H, Takemura S, Yamamoto S, Hai S, Ichika-wa T, Kodai S, Shinkawa H, Sakaguchi H, Tamori A, Habu D, Nishiguchi S. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res 2007; 37: 94-100. [PMID: 17300703 DOI: 10.1111/j.1872-034X.2007.00013.x]
56. Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown R, Cameron A, Ghobrial M, Kam I, Busuttil R, Saab S, Holt C, Emond J, Stiles J, Lukose T, Chang M, Klintmalm G. Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues. Liver Transpl 2013; 19: 1020-1029 [PMID: 23852663 DOI: 10.1002/lt.23703]